Trial · NCT06203457
Results by group61
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 61
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With TEAEs, TESAEs and TEAESIs | Efgartigimod-Efgartigimod | TEAEs | 15 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Placebo-Efgartigimod | TEAEs | 6 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Efgartigimod-Efgartigimod | TESAEs | 0 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Placebo-Efgartigimod | TESAEs | 2 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Efgartigimod-Efgartigimod | TEAESIs | 10 | Participants | |
| Number of Participants With TEAEs, TESAEs and TEAESIs | Placebo-Efgartigimod | TEAESIs | 5 | Participants | |
| Number of CRESS Responders at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 24 | 1 | 0.30 to 25.01 | Participants |
| Number of CRESS Responders at Weeks 24 and 48 | Placebo-Efgartigimod | Week 24 | 4 | 22.53 to 87.12 | Participants |
| Number of CRESS Responders at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 48 | 2 | 2.13 to 32.62 | Participants |
| Number of CRESS Responders at Weeks 24 and 48 | Placebo-Efgartigimod | Week 48 | 2 | 5.34 to 65.87 | Participants |
| Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 24 | 3 | 4.99 to 39.56 | Participants |
| Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48 | Placebo-Efgartigimod | Week 24 | 2 | 5.34 to 65.87 | Participants |
| Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 48 | 1 | 0.30 to 25.01 | Participants |
| Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48 | Placebo-Efgartigimod | Week 48 | 2 | 5.34 to 65.87 | Participants |
| Number of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 24 | 9 | 31.08 to 73.99 | Participants |
| Number of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48 | Placebo-Efgartigimod | Week 24 | 4 | 22.53 to 87.12 | Participants |
| Number of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 48 | 7 | 21.19 to 63.60 | Participants |
| Number of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48 | Placebo-Efgartigimod | Week 48 | 3 | 12.88 to 77.47 | Participants |
| Number of Participants With Minimal Clinically Important Improvement From Baseline in clinESSDAI at Weeks 24 and 48 | Efgartigimod-Efgartigimod | Week 24 | 2 | 2.13 to 32.62 | Participants |
| Number of Participants With Minimal Clinically Important Improvement From Baseline in clinESSDAI at Weeks 24 and 48 | Placebo-Efgartigimod | Week 24 | 2 | 5.34 to 65.87 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06203457/results